Pharmacotherapy of bone metastases in breast cancer patients

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 937-945

  Petrut, Bianca ^a   Simmons, Christine ^b   Broom, Reuben ^b   Trinkaus, Mateya ^b   Clemonst, Mark ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Denosumab; Osteoprotegerin analogues; Skeletal related events

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; CATHEPSIN K INHIBITOR; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 7 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN ANTIBODY; PLACEBO; PROSTAGLANDIN; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT OSTEOPROTEGERIN; VASCULOTROPIN; VITRONECTIN RECEPTOR INHIBITOR; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; HYPOCALCEMIA; LOADING DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 42649126767     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.937     Document Type: Review

References (48)

1. Muzaffer C, Oursler MJ. Breast cancer bone metastases and current small therapeutics. Cancer Metastasis Rev 2006;25:635-44
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6
3. Warr D, Johnston M. Use of Bisphosphonates in Women with Breast Cancer. Practice Guideline Report#1-11, version 2.2002 updated 2004
4. Hillner BE, Ingle JN, Chlebowski RT, et al. Update on the role of bisphosphonates and bone health. J Clin Oncol 2003;21:4042-57
5. Lipton A. Pathophysiology of bone metastasis: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004;2:11-5]
6. Santini D, Vincenzi B, Dicuozo G, et al. Zoledronic acid induces long lasting modification of circulating angiogenic factors in cancer patients. Clin Can Research 2003;9:2693-97
7. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:460-9
8. Pavlakis N, Stockler M. Bisphosphonates for breast cancer: editorial. BMJ 2002;325:1051-2
9. Plunkett T, Smith P, Rubens R. Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 2000;36:476-82
10. Paterson AH, Powles TJ, Kanis JA, et al. Double blind controlled trial of oral clodrinate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11(1):59-65
11. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;256(1):67-74
12. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001;88(7):701-7
13. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastastic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998:16(6):2038-44
14. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17(3):846-54
15. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082-90
16. Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19(4C):3383-92
17. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14(9):2552-9
18. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14(9):1399-405
19. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastastic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004;90(6):1133-7
20. Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastastic bone disease and breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004;15(5):743-50
21. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23(15):331-21
22. Verma S, Cresswell K, Dranitsaris G, et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer 2004;12:852-8
23. Jagdev SP, Purohito P. Heatley S, Coleman RE. Comaprison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-8
24. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98:1735-7
25. Cameron D, Fallon M, Diel I. Ibandronate its role in metastatic breast cancer. Oncologist 2006;11:27-33
26. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002;(2)
27. Body JJ, Bergstrom B. Improving metastatic bone pain management with ibandronate in patients with breast cancer. Proceedings of the San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2004;88Suppl.(1):Abstract 3065
28. Clemons M, Dranitsaris G, Ooi W, Cole D. A phase II trial evaluating the palliative benefit of second line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate therapy. Breast Cancer Res Treat 2007;102(3):253-381
29. Clemons M, Dranitsaris G, Cole D, Gainford M. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 2006;11:227-33
30. Brown JE, Thomson C, Ellis S, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-7
31. Vinholes JJ, Purohit OP, Abbey ME, et al. Relationship between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-50
32. Coleman RE. The clinical use of bone resorption markers in malignant bone disease. Cancer 2002;94:2521-33
33. Clemons M, Cole D, Grainford M. Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat 2006;97:81-90
34. Coleman RE, Major P, Lipton A, et al. The predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35
35. Lipton A, Cook R, Coleman RE, et al. Normalization of bone markers and improved survival during zoledronic add therapy. J Clin Oncol 2007;25(20):9013-4
36. Clemons M, Dranitsaris G, Ooi W, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24(30):4895-900
37. Kokufu I, Yamamoto M, Noda T, Hiratsuka H. Long-term safety and efficacy of bisphosphonate (BP) therapy for more than 24 months (M) in breast cancer (BC) patients (pts) with bone metastasis (BM). J Clin Oncol 2005;23(16S):816-7
38. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor induced bone disease. Nat Clin Pract Oncol 2007;4(1):42-55
39. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9
40. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9:14-27
41. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892
42. Ooi W, Popovic S, Kalina M, et al. Mechanisms of bone metastasis (BM) growth in patients with metastatic breast cancer (MBC): an exploratory study. J Clin Oncol 2007;25:1102
43. Lipton A, Alvarado C, De Boer R, et al. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). J Clin Oncol 2006;24(18S):512
44. Body JJ, Facon T, Coleman RE. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
45. Ingunn H, Cross SS, Neville-Webbe H, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumors in vivo - a role in tumor cell survival? Breast Cancer Res Treat 2005;92:207-15
46. Aldridge SE, Lennard TW, Williams JR, Birch MA. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 2005;92:1531-7
47. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006;12:6243-9
48. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769-73